ASPEN PHARMACARE HOLDINGS LIMITED - Commercial Release of Locally Manufactured Human Insulin

Commercial Release of Locally Manufactured Human Insulin

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively "Aspen" or "the Company" or "the Group")


COMMERCIAL RELEASE OF LOCALLY MANUFACTURED HUMAN INSULIN

Aspen is pleased to announce that it has received approval from the South African Health Products
Regulatory Authority and will commence the release of the first commercial batches of human insulin
manufactured for sale in South Africa. The products were manufactured at Aspen's sterile finished dose
form manufacturing facility in Gqeberha, Eastern Cape. This milestone marks the commencement of
commercialisation under Aspen's human insulin contract manufacturing agreement.


Durban

5 May 2026

Sponsor
Investec Bank Limited

Date: 05-05-2026 11:20:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.